地塞米松治疗急性呼吸窘迫综合征:多中心随机对照试验
在西班牙17个ICU开展的多中心随机对照试验,纳入277例中重度ARDS患者,比较早期静脉地塞米松(20mg×5天,后10mg×5天)与常规重症监护。
要点
- 早期地塞米松可增加中重度ARDS患者28天无机械通气天数
- 地塞米松组60天全因死亡率显著低于对照组(21% vs 36%)
- 两组不良事件比例无显著差异,最常见为高血糖和ICU新发感染
核心结论
- 早期使用地塞米松可缩短已确立的中重度ARDS患者的机械通气时间并降低总体死亡率。
研究设计与样本
- 多中心随机对照试验,在西班牙17个教学医院ICU开展,纳入277例已确立的中重度ARDS患者,随机分为地塞米松组139例和对照组138例,按意向性治疗分析。
主要发现
- 不良事件比例两组无显著差异,最常见为ICU高血糖(地塞米松组105例[76%] vs 对照组97例[70%])、ICU新发感染(33例[24%] vs 35例[25%])和气压伤(14例[10%] vs 10例[7%])。
关键数值与推荐
- 地塞米松方案:第1-5天静脉20 mg每日一次,第6-10天减为10 mg每日一次。
- 主要结局为28天无机械通气天数,次要结局为随机后60天全因死亡率。
临床怎么用
- 对已确立的中重度ARDS患者,可考虑早期静脉使用地塞米松(20mg×5天,后10mg×5天)以缩短机械通气时间并降低死亡率。
- 治疗期间需监测高血糖、新发感染和气压伤等不良事件。
局限性
- 试验因入组率低在纳入277/314例计划样本后提前终止。
- 研究仅在西班牙17个ICU进行,外推性需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is no proven specific pharmacological treatment for patients with the acute respiratory distress syndrome (ARDS). The efficacy of corticosteroids in ARDS remains controversial. We aimed to assess the effects of dexamethasone in ARDS, which might change pulmonary and systemic inflammation and result in a decrease in duration of mechanical ventilation and mortality. METHODS: We did a multicentre, randomised controlled trial in a network of 17 intensive care units (ICUs) in teaching hospitals across Spain in patients with established moderate-to-severe ARDS (defined by a ratio of partial pressure of arterial oxygen to the fraction of inspired oxygen of 200 mm Hg or less assessed with a positive end-expiratory pressure of 10 cm H2O or more and FiO2 of 0·5 or more at 24 h after ARDS onset). Patients with brain death, terminal-stage disease, or receiving corticosteroids or immunosuppressive drugs were excluded. Eligible patients were randomly assigned based on balanced treatment assignments with a computerised randomisation allocation sequence using blocks of 10 opaque, sealed envelopes to receive immediate treatment with dexamethasone or continued routine intensive care (control group). Patients in the dexamethasone group received an intravenous dose of 20 mg once daily from day 1 to day 5, which was reduced to 10 mg once daily from day 6 to day 10. Patients in both groups were ventilated with lung-protective mechanical ventilation. Allocation concealment was maintained at all sites during the trial. Primary outcome was the number of ventilator-free days at 28 days, defined as the number of days alive and free from mechanical ventilation from day of randomisation to day 28. Secondary outcome was all-cause mortality 60 days after randomisation. All analyses were done according to the intention-to-treat principle. This study is registered with ClinicalTrials.gov, NCT01731795. FINDINGS: Between March 28, 2013, and Dec 31, 2018, we enrolled 277 patients and randomly assigned 139 patients to the dexamethasone group and 138 to the control group. The trial was stopped by the data safety monitoring board due to low enrolment rate after enrolling more than 88% (277/314) of the planned sample size. The mean number of ventilator-free days was higher in the dexamethasone group than in the control group (between-group difference 4·8 days [95% CI 2·57 to 7·03]; p<0·0001). At 60 days, 29 (21%) patients in the dexamethasone group and 50 (36%) patients in the control group had died (between-group difference -15·3% [-25·9 to -4·9]; p=0·0047). The proportion of adverse events did not differ significantly between the dexamethasone group and control group. The most common adverse events were hyperglycaemia in the ICU (105 [76%] patients in the dexamethasone group vs 97 [70%] patients in the control group), new infections in the ICU (eg, pneumonia or sepsis; 33 [24%] vs 35 [25%]), and barotrauma (14 [10%] vs 10 [7%]). INTERPRETATION: Early administration of dexamethasone could reduce duration of mechanical ventilation and overall mortality in patients with established moderate-to-severe ARDS. FUNDING: Fundación Mutua Madrileña, Instituto de Salud Carlos III, The European Regional Development's Funds, Asociación Científica Pulmón y Ventilación Mecánica.
引用
- Villar J, Ferrando C, Martínez D, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med. 2020. PMID: 32043986. doi:10.1016/S2213-2600(19)30417-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。